West Pharmaceutical Services reported adjusted second-quarter 2026 earnings per share of $2.37, a 28.8% year-over-year increase that beat the Zacks Consensus Estimate by 13.9%. Revenue rose 13.8% to $872.3 million, exceeding estimates by 4.2%, driven by a 16.6% jump in Proprietary Products segment sales to $722.6 million. Within that segment, high-value product components grew 19.4% and high-value product delivery devices surged 29.6%, with the latter representing 15% of total company net sales. The company raised its full-year 2026 adjusted EPS guidance to a range of $8.85 to $9.05, up from the prior $8.40 to $8.75, and lifted its revenue forecast to between $3.345 billion and $3.380 billion. Shares rose approximately 6% in pre-market trading following the results.
Cardinal Health Inc
McKesson Corporation
Phibro Animal Health CorporationWest Pharmaceutical Services IncWest Pharmaceutical reported Q2 earnings and sales beat and raised 2026 guidance.